Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04291755 · ClinicalTrials.gov registry record

Development and Analysis of a Stool Bank for Cancer Patients

A clinical trial of Carcinoma, Non-Small Cell Lung and Carcinoma, Colorectal, sponsored by Persephone Biosciences.

Recruiting
Registry status
100
Enrollment target
2
Study locations

NCT04291755 is a study of Carcinoma, Non-Small Cell Lung and Carcinoma, Colorectal that is actively recruiting participants, run by Persephone Biosciences. The registered enrollment target is 100 participants, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (69% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04291755, a study of Carcinoma, Non-Small Cell Lung and Carcinoma, Colorectal, is actively recruiting participants, sponsored by Persephone Biosciences.

RECRUITING
Registry status
100 participants
Enrollment target
2
Study locations

Study Summary

This study is aimed at understanding the impact of gut microbiota on efficacy of cancer therapies, in particular checkpoint inhibitors, and using the resulting information to design microbial immunotherapies. Although animal models are of use to determine the influences of gut and other microbiota on cancer treatment modalities, they are limited due to differences between mouse and human physiology and immunology, as well as the inherent differences in gut microbial populations between the two mammalian organisms. Therefore, samples obtained as donations from human subjects undergoing cancer treatment are of great value for the identification and determination of bacteria and their metabolic processes that are involved in the successful cure and remission of cancer by checkpoint inhibitor therapies. The objective of this study is to collect 3 samples each of blood, urine, and stool in subjects with cancer. This is a non-interventional, 2 site study in 100 people who are undergoing any type of cancer immunotherapy. Subjects who meet the entry criteria will provide 5 samples each of blood, urine, and stool over a 12-month period.

Conditions Studied

Carcinoma, Non-Small Cell Lung Carcinoma, Colorectal

Interventions

  • DRUG Pembrolizumab Injection

Study Locations (2)

California

  • Compassionate Care Research Group, Inc. - Fountain Valley

Florida

  • Bond and Steele Clinic, P.A. - Winter Haven

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2019-06-28
Est. Completion 2028-12-31

Sponsor

Persephone Biosciences

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04291755

The ClinicalTrials.gov registry entry for NCT04291755 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (69% lower). The listed sponsor is Persephone Biosciences, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab Injection is the first listed.

NCT04291755 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Florida.

Frequently Asked Questions

What is clinical trial NCT04291755 about?

NCT04291755 is a clinical study titled "Development and Analysis of a Stool Bank for Cancer Patients". This study is aimed at understanding the impact of gut microbiota on efficacy of cancer therapies, in particular checkpoint inhibitors, and using the resulting information to design microbial immunotherapies. Although animal models are of use to determine the influences of gut and other microbiota o...

What is the current status of trial NCT04291755?

This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2019-06-28. Estimated completion is 2028-12-31.

What conditions does trial NCT04291755 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Carcinoma, Colorectal.

What interventions are being tested in trial NCT04291755?

The interventions under investigation include: Pembrolizumab Injection (DRUG).

Who is sponsoring clinical trial NCT04291755?

This trial is sponsored by Persephone Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04291755 being conducted?

This trial has 2 study locations across California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Non-Small Cell Lung

All registered trials for this condition

Carcinoma, Colorectal

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.